Sign In
Buy SPRY
$8.75
-0.150 (-1.69%)
At Close: Jun 03, 2026
Initial $100 million term loan to propel market share growth in the U.S. SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical co
ARS Pharmaceuticals: A Significant Upside Is Expected From neffy
02:08am, Tuesday, 23'rd Sep 2025
ARS Pharmaceuticals offers significant upside driven by neffy, the only FDA-approved needle-free epinephrine nasal spray for severe allergic reactions. ARS faces near-term pressure from a patent chall
ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair
09:00am, Wednesday, 17'th Sep 2025
– Accomplished biopharma executive and entrepreneur brings a 25-year track record of upscaling valuable companies and realizing the potential of their innovations – SAN DIEGO, Sept. 17, 2025 (GLOB
Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis
08:00am, Monday, 08'th Sep 2025
Findings accepted for publication in the official journal of the American College of Allergy, Asthma and Immunology About 9 out of every 10 patients experiencing anaphylaxis were effectively treated w
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Thursday, 28'th Aug 2025
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect them
ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript
11:53am, Wednesday, 13'th Aug 2025
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Eric Karas - Chief Commercial Officer Justin Chakma - Chief Business Officer K
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates
09:15am, Wednesday, 13'th Aug 2025
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.13 per share a year ago.
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)
07:00am, Wednesday, 13'th Aug 2025
$15.7 million in revenue, including $12.8 million in neffy U.S. net product revenue in second quarter of 2025
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results
08:00am, Monday, 04'th Aug 2025
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patie
Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for
11:10am, Tuesday, 29'th Jul 2025
ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EUR neffy ( neffy ® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children ( > 30 kg) living with severe allergic reactions
ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy?
01:01pm, Tuesday, 15'th Jul 2025
Does ARS Pharmaceuticals, Inc. (SPRY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High?
10:56am, Tuesday, 15'th Jul 2025
The mean of analysts' price targets for ARS Pharmaceuticals, Inc. (SPRY) points to a 78.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem
What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing'
09:50am, Tuesday, 15'th Jul 2025
ARS Pharmaceuticals, Inc. (SPRY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that ma
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 27'th May 2025
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect thems
